<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005936</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0831</org_study_id>
    <secondary_id>NCI-2021-05381</secondary_id>
    <secondary_id>2020-0831</secondary_id>
    <nct_id>NCT05005936</nct_id>
  </id_info>
  <brief_title>Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment</brief_title>
  <official_title>Comparing the Performance of Automated Breast Ultrasonography (ABUS) to Hand-Held Breast Ultrasonography (WBUS) in Breast Cancer Treatment Response Assessment in a Tertiary Cancer Center: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the performance of automated breast ultrasonography and conventional&#xD;
      hand-held whole breast ultrasonography when checking for response to breast cancer treatment.&#xD;
      Breast ultrasonography is operator dependent and time-intensive. Automated breast&#xD;
      ultrasonography scanners were developed to allow standardization of ultrasound scanning and&#xD;
      scanning to be performed by any technologist, with or without previous ultrasound experience,&#xD;
      without physician involvement. This study may validate the use of the automated breast&#xD;
      ultrasonography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate and compare the accuracy of automated breast ultrasonography (ABUS) and&#xD;
      hand-held whole breast ultrasonography (WBUS) in predicting pathology complete response (pCR)&#xD;
      with relative tumor volume change, using the receiver operating characteristic (ROC) curve&#xD;
      analysis.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the reproducibility of tumor volume measurements obtained by ABUS and handheld&#xD;
      WBUS, respectively, using data collected at baseline for initial staging.&#xD;
&#xD;
      II. To assess the agreement in relative tumor volume change (RC) (end-of-treatment versus&#xD;
      [vs.] pre-treatment) between ABUS and WBUS.&#xD;
&#xD;
      III. To estimate and compare the following diagnostic measures for ABUS and WBUS:&#xD;
      sensitivity, specificity, positive predictive value (PPV) and negative predictive value&#xD;
      (NPV).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline,&#xD;
      mid-treatment and pre-surgery (end of treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the receiver operating characteristic (ROC) curve</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Will compute relative tumor volume change for both automated breast ultrasonography (ABUS) and hand-held whole breast ultrasonography (WBUS) and estimate pathology complete response ROC curves for each. Will estimate the areas under the ROC curves along with 95% confidence intervals and then compare the values statistically.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor volume</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Will compute the intraclass correlation coefficient for each method along with 95% confidence intervals and then compare these estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative tumor volume change</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Will compute the relative change in tumor volume for ABUS and WBUS and assess their agreement using the Bland-Altman approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The cutoff point will be determined using Youden Index, i.e., the point that maximize (sensitivity specificity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The cutoff point will be determined using Youden Index, i.e., the point that maximize (sensitivity specificity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (ABUS, WBUS)</arm_group_label>
    <description>Patients undergo ABUS over 15 minutes followed by WBUS over 30 minutes at baseline, mid-treatment and pre-surgery (end of treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasonography</intervention_name>
    <description>Undergo ABUS</description>
    <arm_group_label>Ancillary-Correlative (ABUS, WBUS)</arm_group_label>
    <other_name>2-Dimensional Grayscale Ultrasound Imaging</other_name>
    <other_name>2-Dimensional Ultrasound Imaging</other_name>
    <other_name>2D-US</other_name>
    <other_name>Ultrasound</other_name>
    <other_name>Ultrasound Imaging</other_name>
    <other_name>Ultrasound Test</other_name>
    <other_name>Ultrasound, Medical</other_name>
    <other_name>US</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasonography</intervention_name>
    <description>Undergo WBUS</description>
    <arm_group_label>Ancillary-Correlative (ABUS, WBUS)</arm_group_label>
    <other_name>2-Dimensional Grayscale Ultrasound Imaging</other_name>
    <other_name>2-Dimensional Ultrasound Imaging</other_name>
    <other_name>2D-US</other_name>
    <other_name>Ultrasound</other_name>
    <other_name>Ultrasound Imaging</other_name>
    <other_name>Ultrasound Test</other_name>
    <other_name>Ultrasound, Medical</other_name>
    <other_name>US</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer or suspicion of breast cancer seen in MD Anderson Breast&#xD;
        imaging clinic at the Texas Medical Center (TMC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subjects to be studied will include patients seen in MD Anderson Breast imaging&#xD;
             clinic at the Texas Medical Center (TMC)&#xD;
&#xD;
          -  With breast cancer or suspicion of breast cancer&#xD;
&#xD;
          -  Male or female who is older than 18 years of age&#xD;
&#xD;
          -  Of any race&#xD;
&#xD;
          -  Who consent to obtain technologist performed breast ultrasound and automated breast&#xD;
             ultrasound&#xD;
&#xD;
          -  English and non-English speakers (with language interpreter to assist in translation&#xD;
             for non-English speakers)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who is less than 18 years of age&#xD;
&#xD;
          -  Imaging obtained outside of MD Anderson TMC&#xD;
&#xD;
          -  Surgery pathology from outside of MD Anderson will be excluded from this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica L Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Monica L. Huang</last_name>
      <phone>832-817-8514</phone>
      <email>mlhuang@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Monica L. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

